Dmitry Balyasny’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Dmitry Balyasny’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250,000	Closed	-$2.61M	–	3081
2023 Q1	$2.61M	Hold	250,000	–	–	0.01%	1358
2022 Q4	$2.57M	Hold	250,000	–	–	0.01%	1303
2022 Q3	$2.51M	Hold	250,000	–	–	0.01%	1369
2022 Q2	$2.51M	Buy	250,000 +100,000	+67%	+$993K	0.01%	1278
2022 Q1	$1.48M	Buy	+150,000	New	+$1.48M	﹤0.01%	1488

Other funds holding BIOS

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.1B AUM 13.6% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Quarry LP New York $1.2B AUM 47.63% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Dmitry Balyasny's BIOS Position: Q2 2023 in Review

Dmitry Balyasny sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 250,000 shares — an estimated $2.61M sold.

Dmitry Balyasny first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $2.61M in Q1 2023. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

Dmitry Balyasny reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Dmitry Balyasny sold 250,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $2.61M.
Dmitry Balyasny first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
Dmitry Balyasny's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $2.61M in Q1 2023.
32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.